@conference{bd269d81ecf040a3957908dc539e77f4,
title = "Phase I trial of weekly and every-three-weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs).",
author = "\{Guardiola Amado\}, \{Victor D\}",
note = "e13516 Background: S is a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic/antiproliferative properties. Ix is a cytotoxic microtubule-stabilizing semisynthetic epothilone also containing antiproliferative and antiangiogenic effects. IX and S combination may be synergistic, since S may increase delivery of Ix to the tumor by inducing vascular normalization, and the anti-angiogenic effects of S may be enhanced by Ix through HIF-1α regulation.; American Society of Clinical Oncology (ASCO) Annual Meeting ; Conference date: 01-01-2014",
year = "2010",
language = "American English",
}